


## Technical Data Sheet

### Rabbit Anti-LCAR-B38M Monoclonal Antibody, Alexa Fluor 647

Product Information	
Product No.	212702
Size	100 tests
Recommended Vol. per Test	1 $\mu$ L
Antibody Types	Monoclonal
Antibody Format	Whole IgG
Clone	38-1A2
Immunogen	two tandem VHH sequences of LCAR-B38M
Conjugate	Alexa Fluor 647
Excitation/Emission Max	651/667nm
Host Species	Rabbit
Storage Buffer	Aqueous buffered solution containing protein stabilizer and $\leq 0.05\%$ ProClin 300
Storage conditions	2-8°C, store in dark

#### Description

38-1A2 is a specific antibody that binds precisely to two tandem VHH sequences of LCAR-B38M. These sequences are designed to target two epitopes of the B-cell maturation antigen (BCMA). BCMA is a protein expressed selectively by B-lineage cells, including both normal and malignant plasma cells in multiple myeloma. Ciltacabtagene autoleucel, also known as cilta-cel or Carvykti, is a gene-edited autologous CAR T-cell therapy. It utilizes LCAR and B38M to effectively recognize BCMA-positive cells.



*Flow cytometric analysis of anti-LCAR-B38M CAR expression on human cell line Jurkat cells. Jurkat cells were transduced with lentivirus encoding LCAR-B38M CAR and cultured.  $2 \times 10^5$  cells were stained for the expression of Rabbit Anti-LCAR-B38M Monoclonal Antibody, Alexa Fluor 647 (Product No.212702, right panel). Non-transduced Jurkat cells were used as a control for gating of CAR expression (left panel).*

#### Preparation & Storage

- Store undiluted at 2-8°C.
- Avoid prolonged exposure to light.
- Avoid freeze/thaw cycle of the reagent.
- The monoclonal antibody was purified by Protein A.
- The antibody was conjugated with Alexa Fluor 647 under optimum conditions, and unincorporated dye was removed.

#### Application Notes

##### Application

Flow cytometry

Routinely Tested

## Recommended Antibodies to Include in the Detection Process

Product name	Product No.
Anti-human CD45 Antibody	602139/602140
Anti-human CD14 Antibody	602241
Anti-human CD8 Antibody	602006
Anti-human CD3 Antibody	603938/604045
Anti-human CD4 Antibody	601940/604240

### FACS Protocol

#### (Optional) For Whole Blood Sample

1. Pipette 1  $\mu$ L Rabbit Anti-LCAR-B38M Monoclonal Antibody, Alexa Fluor 647 into the bottom of the tube.
2. Add dead cell staining solution and additional fluorochrome conjugated antibodies into the bottom of the tube.
3. Pipette 100  $\mu$ L of well-mixed, anticoagulated whole blood into the bottom of the tube. Mix gently and thoroughly.  
**Note** Avoid smearing sample down the side of the tube. If the sample remains on the side of the tube, it will not be stained with the reagents.
4. Incubate for 25 minutes in the dark at room temperature (18-25°C).
5. Pipette Red Blood Cell Lysis Solution to the tube. Mix gently and thoroughly. Incubate for 15 minutes in the dark at room temperature (18-25°C).
6. Add 500  $\mu$ L FACS buffer to the tube. Mix well and centrifuge at 300g for 5 minutes at room temperature (18-25°C). Aspirate supernatant completely.
7. Repeat step 6 twice.
8. Add a suitable amount of FACS buffer to resuspend cell and analysis by flow cytometry.

#### (Optional) For Cell Sample

1. Harvest the cells and wash the cells twice by FACS buffer.
2. Count the cells number and the viability.
3. Resuspend the cell suspension to a concentration up to  $1 \times 10^6$  nucleated cells per 100  $\mu$ L of buffer.
4. Add 1  $\mu$ L Rabbit Anti-LCAR-B38M Monoclonal Antibody, Alexa Fluor 647, dead cell staining solution and additional fluorochrome. Mix gently and thoroughly.
5. Incubate for 25 minutes in the dark at room temperature (18-25°C).
6. Add 500  $\mu$ L FACS buffer to the tube. Mix well and centrifuge at 300 g for 5 minutes at room temperature (18-25°C). Aspirate supernatant completely.
7. Repeat step 6 twice.
8. Add a suitable amount of FACS buffer to resuspend cell and analysis by flow cytometry.

### Product Notices

1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Caution: Antibody solutions containing ProClin 300 should be handled with care. Do not take internally and avoid all contact with the skin, mucosa and eyes.

### Intellectual Product Notices

1. This product is provided under an intellectual property license from Life Technologies Corporation. The transfer of this product is conditioned on the buyer using the purchased product solely in research conducted by the buyer and the buyer must not (1) use this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; or (b) manufacturing or quality assurance or quality control, and/or (2) sell or transfer this product or its components for resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or [outlicensing@thermofisher.com](mailto:outlicensing@thermofisher.com).
2. Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation of any patents. BioSwan will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of BioSwan Company is strictly prohibited.  
For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resales.  
BioSwan, the BioSwan Logo and all other trademarks are property of BioSwan Laboratories, Co., Ltd.

### References

1. Robert O. Carpenter et al., "B-Cell Maturation Antigen Is a Promising Target for Adoptive T-Cell Therapy of Multiple Myeloma," *Clinical Cancer Research* 19, no. 8 (April 15, 2013): 2048–60, <https://doi.org/10.1158/1078-0432.CCR-12-2422>.
2. Bo Yu, et al., "BCMA-Targeted Immunotherapy for Multiple Myeloma," *Journal of Hematology & Oncology* 13, no. 1 (December 2020): 125, <https://doi.org/10.1186/s13045-020-00962-7>.